
MRNA · NASDAQ-GS
Expected to report Feb 12, 2027 — estimated from last year’s reporting date.
Consensus is -$2.40 EPS for Dec 2026 across 8 estimates, ranging -$4.29 to -$1.86.
Moderna’s Q3 was a seasonal commercial rebound that restored quarterly profitability and prompted a material upgrade to 2026 guidance. Revenue of $1.313 billion increased 29% from $1.016 billion a year ago and was far above Q2’s $145 million, as fall vaccine deliveries lifted COVID sales. Diluted EPS of $0.38 also exceeded expectations for a $1.10 loss. Net income was $162 million, versus a $200 million loss in Q3 2025 and a $782 million loss in Q2; operating income of $130 million compares with operating losses in both periods.
Growth was concentrated in COVID vaccines and international deliveries under government partnerships, while the quarter also brought positive Phase 3 melanoma data for intismeran. The company raised its 2026 revenue-growth range to 15%–25% from up to 10%, lowered R&D expense guidance by $200 million to $2.7 billion, and improved its year-end cash-and-investments outlook to $8.1–$8.3 billion. The balance-sheet improvement reflects both better operating expectations and $2.6 billion of net proceeds from convertible financing; operating cash use remains substantial, and seasonal sales were largely uncollected at quarter-end. Moderna also reported an important pipeline setback: its norovirus Phase 3 interim analysis missed early-success criteria, and it will not enroll another cohort this season.
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A$427.48
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of$21.77
Regeneron Pharmaceuticals, Inc.$917.65
GSK plc American Depositary Shares (Each representing two Ordinary Shares)$47.70